Home › Funds › Fidelity Management & Research (FMR) › AVBP
Fidelity Management & Research (FMR) position in AVBP
ARRIVENT BIOPHARMA INC · Health Care
Latest position (Q2 2026)2.78M sh
Reported value held$96.54M
Portfolio Weight0.00%
First reportedQ1 2024
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 1.95M | $34.83M | New |
| Q2 2024 | 1.95M | $36.18M | Hold |
| Q3 2024 | 2.12M | $49.81M | Add |
| Q4 2024 | 2.10M | $55.97M | Reduce |
| Q1 2025 | 2.08M | $38.43M | Reduce |
| Q2 2025 | 2.06M | $44.80M | Reduce |
| Q3 2025 | 3.41M | $62.87M | Add |
| Q4 2025 | 3.70M | $74.52M | Add |
| Q1 2026 | 3.02M | $69.58M | Reduce |
| Q2 2026 | 2.78M | $96.54M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding AVBP
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $136.50M · Q2 2026
- BlackRock Inc 3.25M sh · $112.92M · Q2 2026
- Vanguard Group 1.87M sh · $37.61M · Q4 2025
- Geode Capital Management 972.63K sh · $33.80M · Q2 2026
- D. E. Shaw & Co 872.01K sh · $30.29M · Q2 2026
- Goldman Sachs Group 853.72K sh · $29.66M · Q2 2026
- Point72 Asset Management 566.80K sh · $19.69M · Q2 2026
- Millennium Management 438.66K sh · $15.24M · Q2 2026
- UBS Group AG 438.59K sh · $15.24M · Q2 2026
- Balyasny Asset Management 395.45K sh · $13.74M · Q2 2026
- Northern Trust Corp 332.75K sh · $11.56M · Q2 2026